Levi & Korsinsky notifies investors that it has commenced an investigation into Incyte Corporation (NASAQ: INCY) concerning potential violations of the federal securities laws.
On November 18, 2024, INCY announced it will pause enrollment in the Phase 2 study of its drug INCB000262 in chronic spontaneous urticaria (CSU) due to “the observation of certain in vivo preclinical toxicology findings.” The Company also announced the discontinuation of the development of its drug INCB000547 for patients with cholestatic pruritus (CP). Both of these drugs stem from Incyte’s $750 million acquisition of Escient Pharmaceuticals earlier this year. Following this news, Incyte’s stock price fell by $9.05 per share, or approximately 12% to close at $67.92 per share.
If you suffered a loss on your Incyte Corporation securities and would like to explore a potential recovery under the federal securities laws, submit to us or contact Joseph E. Levi, Esq. via email at [email protected] or call 212-363-7500 to speak to our team of experienced shareholder advocates.
Please provide your address so we can contact you about your case if eligible.






Input your stock purchases and sales












Connect with SnapTrade to let us the stocks you own. This is an optional step to keep you. informed about class action litigation.
✓ Fast: takes less than a min
✓ We do not create an attorney-client relationship
✓ Your information is confidential & secure





